The source of viral hepatitis C is patients and asymptomatic carriers. Hepatitis C virus is a type of hepatitis virus that is transmitted through blood-borne transmission. It is transmitted through blood transfusion and blood products, sexually, through close contact, and from mother to child. Who is more likely to be infected with HCV? In fact, human beings are generally susceptible to HCV, but the main risk groups are those who are frequently exposed to blood, such as hemophiliacs, obstetricians and gynecologists, surgeons, surgeons, extracorporeal circulators for thoracic surgery, renal transplantation hemodialysis patients and oncology patients, and intravenous drug addicts. Hepatitis C virus infection is more likely to be chronic than hepatitis B virus infection, and about half of the cases of acute hepatitis C evolve into chronic hepatitis C. The follow-up of acute hepatitis C cases is very limited. Follow-up observation of acute hepatitis C for 5 years confirms that 60% develop cirrhosis by liver pathologic examination. Japanese and Western data indicate that 70% of post-hepatitis cirrhosis is caused by HCV infection. Hepatitis B epidemic is very serious in China, so hepatitis cirrhosis caused by hepatitis B virus infection is still predominant. On the basis of cirrhosis, it can be transformed into hepatocellular carcinoma, and the incidence of cirrhosis after hepatitis C virus infection is higher than that after hepatitis B virus infection. The incidence of cirrhosis after 25-30 years of hepatitis C virus infection is 5%-25%, and the incidence of hepatic failure after 10 years is 30% in patients with hepatitis C-related cirrhosis, and it generally takes about 20-25 years from hepatitis C to hepatocellular carcinoma. At present, with the research of new drugs for hepatitis C treatment at home and abroad, polyethylene glycol interferon combined with ribavirin has become the standard treatment program for hepatitis C in China, and about 65% of patients can achieve sustained virological response. Therefore, the active and regular early treatment of hepatitis C patients is beneficial to improve the long-term survival rate and quality of life.